[{"id":"de3ecf6b-3b4c-409e-bd4d-5f880ce8753e","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT02187783","created_at":"2021-01-18T10:12:32.699Z","updated_at":"2024-07-02T16:36:57.957Z","phase":"Phase 2","brief_title":"LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)","source_id_and_acronym":"NCT02187783 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDKN2A • CCND1 • CDK4 • CDK6 • CCND3","pipe":" | ","alterations":" CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification","tags":["CDKN2A • CCND1 • CDK4 • CDK6 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 08/25/2014","start_date":" 08/25/2014","primary_txt":" Primary completion: 01/17/2018","primary_completion_date":" 01/17/2018","study_txt":" Completion: 01/17/2018","study_completion_date":" 01/17/2018","last_update_posted":"2019-07-18"}]